Background In living-donor liver transplantation (LDLT), the recipient's portal vein is short. Furthermore, portal vein thrombosis and stenosis can be lethal complications. We had begun the systemic administration of gabexate mesilate, a strong serine protease inhibitor, which has cytoprotective effects of endothelial cells. It is often effective on disseminated intravascular coagulation. The purpose of this study was to examine the effects of gabexate mesilate and to reveal risk factors for portal vein stenosis in LDLT. Methods From 1991 to 2012, we performed 153 LDLTs. For the present cohort study, patients were divided into 2 groups. In group I, we treated with gabexate mesilate mildly (0-20 mg/kg/d; n = 29). In group II, we treated with gabexate mesilate at full dose (40 mg/kg/d; n = 124). We investigated the survival rates of both groups and performed univariate and multivariate analyses to identify the independent risk factors for portal vein stenosis. Results The survival rate of group II was significantly better than that of group I (P <.05). On univariate analysis, the risk factors identified to be associated with a P value of <.20 were old age (P =.0385), heavy body weight (P =.1840), tall height (P =.1122), small lumen diameter of portal vein (P =.1379), high volume of blood loss (P =.0589), small amount of gabexate mesilate infusion (P =.0103), and large graft weight (P =.1326). On multiple logistic regression analysis we identified old age (P =.0073) and small amount of gabexate mesilate infusion (P =.0339) to be the independent risk factors for portal vein stenosis. Conclusions On multivariate analysis, we found that gabexate mesilate infusion contributed to the reduction of portal vein stenosis.
|Number of pages||3|
|Publication status||Published - 2014 Apr|
ASJC Scopus subject areas